Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Completed · Phase 1
Conditions studied: Lung Cancer, Metastatic Cancer
In brief
RATIONALE: Romidepsin and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of romidepsin when given together with erlotinib hydrochloride and to see how well they work in treating patients with stage III or stage IV non-small cell lung cancer.
Key facts
- Study ID
- NCT01302808
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 17
- Starts
- 2009-09-01
- Expected to finish
- 2014-12-01
- Last updated by the study team
- 2021-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.